- Home
- BCC vs RNA Comparison
BCC vs RNA Comparison
Compare BCC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCC
- RNA
- Stock Information
- Founded
- BCC 2004
- RNA 2012
- Country
- BCC United States
- RNA United States
- Employees
- BCC N/A
- RNA N/A
- Industry
- BCC RETAIL: Building Materials
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- BCC Consumer Discretionary
- RNA Health Care
- Exchange
- BCC Nasdaq
- RNA Nasdaq
- Market Cap
- BCC 3.9B
- RNA 3.2B
- IPO Year
- BCC 2013
- RNA 2020
- Fundamental
- Price
- BCC $93.47
- RNA $26.66
- Analyst Decision
- BCC Buy
- RNA Strong Buy
- Analyst Count
- BCC 7
- RNA 12
- Target Price
- BCC $127.67
- RNA $68.25
- AVG Volume (30 Days)
- BCC 445.3K
- RNA 1.9M
- Earning Date
- BCC 05-05-2025
- RNA 05-08-2025
- Dividend Yield
- BCC 6.24%
- RNA N/A
- EPS Growth
- BCC N/A
- RNA N/A
- EPS
- BCC 9.57
- RNA N/A
- Revenue
- BCC $6,724,294,000.00
- RNA $10,897,000.00
- Revenue This Year
- BCC $1.23
- RNA N/A
- Revenue Next Year
- BCC $5.11
- RNA $135.33
- P/E Ratio
- BCC $9.77
- RNA N/A
- Revenue Growth
- BCC N/A
- RNA 13.98
- 52 Week Low
- BCC $87.84
- RNA $21.51
- 52 Week High
- BCC $155.42
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- BCC 41.51
- RNA 45.21
- Support Level
- BCC $91.43
- RNA $25.28
- Resistance Level
- BCC $96.80
- RNA $27.67
- Average True Range (ATR)
- BCC 4.97
- RNA 2.36
- MACD
- BCC 0.17
- RNA -0.03
- Stochastic Oscillator
- BCC 39.51
- RNA 56.41
About BCC Boise Cascade L.L.C.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two segments namely Wood Products and Building Materials Distribution. Wood Products segment manufactures EWP, consisting of laminated veneer lumber (LVL), I-joists, and laminated beams. The Building Materials Distribution segment is engaged in the wholesale of building materials. It distributes products such as plywood, OSB, and lumber items such as siding, doors, metal products, insulation, and roofing, EWP and others. The company generates a majority of its revenue from the Building Material Distribution segment.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.